Physician profile
Eduardo Besser
NPI 1972561280
$36,988.84
in general payments reported to CMS, 2019-2025
27 companies · $5,325 in 2025
The $5,325 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $98.36 · 2021: $148 · 2022: $2,591 · 2023: $18K · 2024: $9,778 · 2025: $5,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $6,000 · Travel and Lodging: $1,720 · Consulting Fee: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,600.00 |
| Food and Beverage | $6,000.14 |
| Travel and Lodging | $1,719.61 |
| Consulting Fee | $1,237.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $27,626.49 | 2023-2025 | Quatera 700, Callisto Eye, Cirrus Hd-Oct |
| Carl Zeiss Meditec USA, INC. | $2,194.00 | 2022-2025 | Quatera 700, Veracity Surgical, Iolmaster 700 |
| Bausch & Lomb Americas INC. | $1,883.36 | 2022-2025 | Envista Mx60 Iol, Miebo, Doctors Allergy Formula |
| Alcon Vision LLC | $1,371.62 | 2019-2025 | Constellation, Ora System Verifeye, Clareon |
| Glaukos Corporation | $653.88 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $411.84 | 2019 | |
| Abbvie INC. | $308.47 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Horizon Therapeutics Plc | $293.89 | 2021-2023 | Tepezza |
| Ocular Therapeutix, INC. | $293.06 | 2022-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $275.98 | 2023-2025 | Cequa |
| New World Medical,INC. | $258.86 | 2023 | |
| Rxsight INC | $245.84 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $182.46 | 2024-2025 | Xdemvy |
| Allergan, INC. | $177.35 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $161.59 | 2022-2023 | Catalys System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.70 | 2024-2025 | Tepezza |
| Nova Eye, INC. | $107.07 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $96.53 | 2022-2023 | |
| Rayner Intraocular Lenses Limited | $85.22 | 2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Thea Pharma INC. | $47.30 | 2023-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $41.61 | 2022-2025 | Tyrvaya |
| Sight Sciences, INC. | $37.60 | 2022 | |
| Dompe US, INC. | $35.21 | 2025 | Oxervate |
| Biotissue Holdings INC. | $22.11 | 2022 | |
| Kala Pharmaceuticals, INC. | $20.97 | 2022 | |
| Aerie Pharmaceuticals, INC. | $20.73 | 2021 | |
| Halozyme INC | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Besser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.